Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
2.
Bioorg Med Chem Lett ; 20(5): 1524-7, 2010 Mar 01.
Article in English | MEDLINE | ID: mdl-20149657

ABSTRACT

Morphing structural features of HTS-derived chemotypes led to the discovery of novel 2-cyano-pyrimidine inhibitors of cathepsin K with good pharmacokinetic profiles, for example, compound 20 showed high catK potency (IC(50)=4nM), >580-fold selectivity over catL and catB, and oral bioavailability in the rat of 52%.


Subject(s)
Cathepsin K/antagonists & inhibitors , Cysteine Proteinase Inhibitors/chemistry , Pyrimidines/chemistry , Administration, Oral , Animals , Binding Sites , Cathepsin K/metabolism , Cell Line , Crystallography, X-Ray , Cysteine Proteinase Inhibitors/chemical synthesis , Cysteine Proteinase Inhibitors/pharmacokinetics , Drug Design , High-Throughput Screening Assays , Humans , Pyrimidines/chemical synthesis , Pyrimidines/pharmacokinetics , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship
3.
Bioorg Med Chem Lett ; 20(21): 6237-41, 2010 Nov 01.
Article in English | MEDLINE | ID: mdl-20843687

ABSTRACT

Several structure-guided optimisation strategies were explored in order to improve the hERG selectivity profile of cathepsin K inhibitor 1, whilst maintaining its otherwise excellent in vitro and in vivo profile. Ultimately, attenuation of clogP and pK(a) properties proved a successful approach and led to the discovery of a potent analogue 23, which, in addition to the desired selectivity over hERG (>1000-fold), displayed a highly attractive overall profile.


Subject(s)
Cathepsin K/antagonists & inhibitors , Ether-A-Go-Go Potassium Channels/drug effects , Nitriles/chemical synthesis , Nitriles/pharmacology , Potassium Channel Blockers/chemical synthesis , Potassium Channel Blockers/pharmacology , Pyrimidines/chemical synthesis , Pyrimidines/pharmacology , Drug Design , Drug Discovery , Indicators and Reagents , Models, Molecular , ROC Curve , Structure-Activity Relationship , Torsades de Pointes/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL